Key Takeaways
- • Branford Castle Partners has completed its sixth add-on acquisition for Lafayette Instrument, acquiring Avisoft Bioacoustics, a Berlin-based maker of ultrasonic microphones and recording software used in life sciences research, with founder Raimund Specht remaining as operator.
- • Avisoft's integrated product suite—UltraSoundGate recording interfaces, RECORDER software, and SASLab Pro analysis tools—serves a durable, niche customer base in neuroscience, behavioral research, and field ecology, with systems referenced in thousands of peer-reviewed papers.
- • The acquisition extends Lafayette's buy-and-build strategy in life sciences instrumentation, following five prior add-ons since 2021 (Aurora Scientific, Actimetrics, Alzet, Sutter Instrument, and Limestone Technologies), consolidating fragmented small-cap specialist makers under a unified platform.
- • The global life-science instrumentation market totaled approximately $70 billion in 2025 and is expanding at 6.5 percent annually, driven by growing pharmaceutical and biotechnology research budgets, providing substantial runway for Branford Castle's consolidation thesis.
- • Branford Castle's investment strategy targets enterprise values up to $100 million with EBITDA of $2 million to $15 million, focusing on niche market positions and specialized manufacturing—a profile exemplified by owner-operated Avisoft and its calibrated hardware-software ecosystem.
Summary
Branford Castle Partners, through its Lafayette Instrument platform, has completed the acquisition of Avisoft Bioacoustics, a privately held German instrumentation company specializing in ultrasonic recording systems for life sciences research. The deal represents the sixth add-on integration since Branford Castle's second fund acquired Lafayette Instrument in 2021, demonstrating sustained execution of a consolidation strategy in fragmented scientific equipment markets.
Avisoft Bioacoustics manufactures integrated hardware and software systems for capturing and analyzing ultrasonic vocalizations—sound frequencies above human hearing range. The company's core product suite comprises three complementary components: the Avisoft-UltraSoundGate recording interface that digitizes high-frequency signals from microphones, the Avisoft-RECORDER multi-channel capture software, and the Avisoft-SASLab Pro analysis platform that converts recordings into spectrograms and quantifiable measurements. The technology serves laboratory neuroscientists studying behavioral markers in neurological disorders, drug responses, and conditions including autism and depression through ultrasonic vocalization recordings in rodent models, while also supporting bat biologists, field ecologists, and animal-communication researchers. The integrated calibration between hardware and software components has enabled the systems to achieve high adoption in academic and pharmaceutical research, with citations across thousands of peer-reviewed scientific publications.
The acquisition builds on Lafayette's prior platform expansion: Aurora Scientific (muscle physiology and neuroscience instrumentation, April 2023), Actimetrics (circadian biology and animal-behavior instruments, November 2023), the Alzet implantable osmotic pump line acquired from DURECT for $17.5 million (December 2024), and Sutter Instrument (electrophysiology and micropipette equipment, May 2026). Each addition targets the same end-customer base of academic and pharmaceutical research institutions, enabling leverage across sales, manufacturing, and technical support infrastructure.
The broader market opportunity underpins the strategy's viability. The global life-science instrumentation market was valued at approximately $70 billion in 2025 and is expanding at 6.5 percent annually, according to market-research analysis cited by the company, driven by expanded pharmaceutical and biotechnology research spending alongside steady laboratory proliferation worldwide. Branford Castle's investment thesis targets precisely the market segment Avisoft occupies: owner-operated, founder-led niche instrument makers with enterprise values under $100 million and EBITDA between $2 million and $15 million. Avisoft, founded by Raimund Specht and headquartered in Glienicke north of Berlin, exemplifies this profile—a specialized, undercapitalized technology with durable customer relationships and limited distribution reach that consolidation can address.
Benjamin Mangrich, CEO of Lafayette Instrument, and Ceon Francis, managing director at Branford Castle, characterized the deal as complementary to Lafayette's existing portfolio while bringing specialized technical expertise. Loy & Co Corporate Finance and RSM provided transaction advisory services.
Avisoft Bioacoustics manufactures integrated hardware and software systems for capturing and analyzing ultrasonic vocalizations—sound frequencies above human hearing range. The company's core product suite comprises three complementary components: the Avisoft-UltraSoundGate recording interface that digitizes high-frequency signals from microphones, the Avisoft-RECORDER multi-channel capture software, and the Avisoft-SASLab Pro analysis platform that converts recordings into spectrograms and quantifiable measurements. The technology serves laboratory neuroscientists studying behavioral markers in neurological disorders, drug responses, and conditions including autism and depression through ultrasonic vocalization recordings in rodent models, while also supporting bat biologists, field ecologists, and animal-communication researchers. The integrated calibration between hardware and software components has enabled the systems to achieve high adoption in academic and pharmaceutical research, with citations across thousands of peer-reviewed scientific publications.
The acquisition builds on Lafayette's prior platform expansion: Aurora Scientific (muscle physiology and neuroscience instrumentation, April 2023), Actimetrics (circadian biology and animal-behavior instruments, November 2023), the Alzet implantable osmotic pump line acquired from DURECT for $17.5 million (December 2024), and Sutter Instrument (electrophysiology and micropipette equipment, May 2026). Each addition targets the same end-customer base of academic and pharmaceutical research institutions, enabling leverage across sales, manufacturing, and technical support infrastructure.
The broader market opportunity underpins the strategy's viability. The global life-science instrumentation market was valued at approximately $70 billion in 2025 and is expanding at 6.5 percent annually, according to market-research analysis cited by the company, driven by expanded pharmaceutical and biotechnology research spending alongside steady laboratory proliferation worldwide. Branford Castle's investment thesis targets precisely the market segment Avisoft occupies: owner-operated, founder-led niche instrument makers with enterprise values under $100 million and EBITDA between $2 million and $15 million. Avisoft, founded by Raimund Specht and headquartered in Glienicke north of Berlin, exemplifies this profile—a specialized, undercapitalized technology with durable customer relationships and limited distribution reach that consolidation can address.
Benjamin Mangrich, CEO of Lafayette Instrument, and Ceon Francis, managing director at Branford Castle, characterized the deal as complementary to Lafayette's existing portfolio while bringing specialized technical expertise. Loy & Co Corporate Finance and RSM provided transaction advisory services.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.